Pharmacokinetics of ADS-5102 (amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia

被引：0
|
作者：
Hauser, Robert [1 ]
Pahwa, Rajesh [2 ]
Wargin, William [3 ]
Souza-Prien, Cindy [4 ]
McClure, Natalie [4 ]
Patni, Rajiv [4 ]
Went, Gregory [4 ]
机构：
[1] Univ South Florida, Tampa, FL USA
[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[3] Nuventra Pharma Serv Inc, Raleigh, NC USA
[4] Adamas Pharmaceut Inc, Emeryville, CA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.043
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
    Cohen, Jeffrey A.
    Hunter, Samuel F.
    Brown, Theodore R.
    Gudesblatt, Mark
    Thrower, Ben W.
    Llorens, Lily
    Souza-Prien, Cindy J.
    Ruby, April E.
    Chernoff, David N.
    Patni, Rajiv
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (04) : 601 - 609
  • [22] INROADS: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment
    Cameron, Michelle
    Cohen, Jeffrey
    Miller, Aaron
    Goodman, Andrew
    Goldman, Myla
    Elfont, Robert
    Souza-Prien, Cindy
    Felt, Larissa
    Patni, Rajiv
    NEUROLOGY, 2019, 92 (15)
  • [23] Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson's disease patients
    Pahwa, R.
    Garrison, L.
    Zimmerman, M.
    Johnson, R.
    Nguyen, J.
    Li, M.
    Patni, R.
    MOVEMENT DISORDERS, 2018, 33 : S398 - S398
  • [24] Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson's disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
    Tanner, C.
    Chernick, D.
    Formella, A.
    MOVEMENT DISORDERS, 2020, 35 : S426 - S426
  • [25] ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
    Hauser, Robert A.
    Pahwa, Rajesh
    Tanner, Caroline M.
    Oertel, Wolfgang
    Isaacson, Stuart H.
    Johnson, Reed
    Felt, Larissa
    Stempien, Mary Jean
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (03) : 511 - 522
  • [26] Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers
    Troy, SM
    Dilea, C
    Martin, PT
    Leister, CA
    Fruncillo, RJ
    Chiang, ST
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (08): : 504 - 514
  • [27] Update to interim results of a long-term open-label safety study of ADS-5102 (amantadine HCl) extended-release capsules for treatment of levodopa-induced dyskinesia (LID) (EASE LID 2 Study)
    Hauser, Robert
    Pahwa, Rajesh
    Tanner, Caroline
    Oertel, Wolfgang
    Johnson, Reed
    Felt, Larissa
    Stempien, Mary
    MOVEMENT DISORDERS, 2017, 32 : S42 - S43
  • [28] THE EFFECTS OF ONCE-DAILY OPICAPONE 50 MG ON THE PHARMACOKINETICS OF LEVODOPA ADMINISTERED AS CARBIDOPA/LEVODOPA EXTENDED-RELEASE CAPSULES: AN OPEN-LABEL STUDY
    Klepitskaya, O.
    Vijan, A.
    Olson, K.
    O'Reilly, T.
    Liang, G.
    Loewen, G.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 44 - 44
  • [29] A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment
    Cohen, Jeffrey A.
    Cameron, Michelle H.
    Goldman, Myla D.
    Goodman, Andrew D.
    Miller, Aaron E.
    Rollins, Anne
    Llorens, Lily
    Patni, Rajiv
    Elfont, Robert
    Johnson, Reed
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 817 - 830
  • [30] Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant
    DuBay, Derek A.
    Teperman, Lewis
    Ueda, Kimi
    Silverman, Andrew
    Chapman, William
    Alsina, Angel E.
    Tyler, Carmelina
    Stevens, Daniel R.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (08): : 995 - 1008
12345